The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study’s patient-level data with fidelity to the original research protocol
Open accessAbstract
Objective: Reanalyse the patient-level data set of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study with fidelity to the original research protocol and related publications. Design: The study was open label and semirandomised examining the effectiveness of up to four optimised and increasingly aggressive, antidepressant therapies in depressed adults. Patients who failed to gain adequate relief from their level 1 trial on the SSRI citalopram could receive up to three additional treatment trials in levels 2–4. Setting: 41 North American psychiatry and primary care treatment centres. Participants: 4041 adults screened positive for major depressive disorder. In contrast to most clinical trials, STAR*D enrolled patients seeking care (vs recruited) and included patients with a wide range of common comorbid medical and psychiatric conditions to enhance the generalisability of findings to real-world clinical practice. Interventions: STAR*D evaluated the relative effectiveness of 13 antidepressants therapies in treatment levels 2–4 for depressed patients who failed to gain adequate benefit from their level 1 medication trial. Main outcome measures: According to the STAR*D protocol, the primary outcome was remission, defined as a score <8 on the blinded Hamilton Rating Scale for Depression (HRSD). Response was a secondary outcome defined as ≥50% reduction in HRSD scores. STAR*D’s protocol specifically excluded all non-blinded clinic-administered assessments from use as research outcome measures. Results: STAR*D investigators did not use the protocol-stipulated HRSD to report cumulative remission and response rates in their summary article and instead used a non-blinded clinic-administered assessment. This inflated their report of outcomes, as did their inclusion of 99 patients who scored as remitted on the HRSD at study outset as well as 125 who scored as remitted when initiating their next-level treatment. These patients should have been excluded from data analysis. In contrast to the STAR*D-reported 67% cumulative remission rate after up to four antidepressant treatment trials, the rate was 35.0% when using the protocol-stipulated HRSD and inclusion in data analysis criteria. Conclusion: STAR*D’s cumulative remission rate was approximately half of that reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 STAR*D’s step-by-step cumulative remission rate presented three ways. The step-by-step theoretical remission rates were obtained from the STAR*D summary article where it states: ‘The theoretical cumulative remission rate is 67% (37+19+6+5).’ [Rush AJ et al,7 p1910]. The HRSD+QIDS SR cumulative remission rate was taken from table 1. It combines the 1089 patients with an exit HRSD score of<8 with the 195 patients who were missing an exit HRSD score but had a final clinic-visit QIDS-SR score of<6. The RIAT Reanalysis cumulative remission rate is based on an exit HRSD score of <8 as the sole measure of remission for the 3110 patients who met STAR*D’s inclusion for data analysis criteria. HRSD, Hamilton Rating Scale for Depression; QIDS-SR, Quick Inventory of Depressive Symptomatology–Self Report; RIAT, Restoring Invisible and Abandoned Trial; STAR*D, Sequenced Treatment Alternatives to Relieve Depression.](https://figures.cochat.ai/paper-figures/15091bf22e1b43f7b72d5aad48ff6ace/what-are-the-treatment-remission-response-and-extent-of-improvement-rates-after-figure-3.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829 · cited 1×
“Objective Reanalyse the patient-level data set of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study with fidelity to the original research protocol and related publications.”
MethodSequenced treatment alternatives to relieve depression (STAR*D): Rationale and design
Rush, A. J., Fava, M., Wisniewski, S. R., Lavori, P. W., Trivedi, M. H., Sackeim, H. A., Thase, M. E., Nierenberg, A. A., Quitkin, F. M., Kashner, T. M., et al. (2004) · Controlled Clinical Trials · doi:10.1016/s0197-2456(03)00112-0 · Cited by 1,076
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Rush, A. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.11.1905 · Cited by 870
Nierenberg, A. A., Fava, M., Trivedi, M. H., Wisniewski, S. R., Thase, M. E., McGrath, P. J., Alpert, J. E., Warden, D., Luther, J. F., Niederehe, G., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1519 · Cited by 559
Fava, M., Rush, A. J., Trivedi, M. H., Nierenberg, A. A., Thase, M. E., Sackeim, H. A., Quitkin, F. M., Wisniewski, S., Lavori, P. W., Rosenbaum, J. F., et al. (2003) · Psychiatric Clinics of North America · doi:10.1016/s0193-953x(02)00107-7 · Cited by 519
Rush, A. J., Bernstein, I. H., Trivedi, M. H., Carmody, T. J., Wisniewski, S., Mundt, J. C., Shores-Wilson, K., Biggs, M. M., Woo, A., Nierenberg, A. A., et al. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.08.022 · Cited by 385
Fava, M., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Alpert, J. E., McGrath, P. J., Thase, M. E., Warden, D., Biggs, M., Luther, J. F., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.7.1161 · Cited by 362
McGrath, P. J., Stewart, J. W., Fava, M., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Thase, M. E., Davis, L., Biggs, M. M., Shores-Wilson, K., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.9.1531 · Cited by 350 · cited 1×
“Objective Reanalyse the patient-level data set of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study with fidelity to the original research protocol and related publications.”
MethodNational Institute of Mental Health (NIMH)
(2008) · Encyclopedia of Global Health · doi:10.4135/9781412963855.n834 · Cited by 348
Efficacy and effectiveness of antidepressants: current status of research
Pigott, H. E., Leventhal, A. M., Alter, G. S., & Boren, J. J. (2010) · Psychotherapy and Psychosomatics · doi:10.1159/000318293 · Cited by 347
Self-citationWisniewski, S. R., Rush, A. J., Nierenberg, A. A., Gaynes, B. N., Warden, D., Luther, J. F., McGrath, P. J., Lavori, P. W., Thase, M. E., Fava, M., et al. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08071027 · Cited by 223
Venlafaxine for Treatment-Resistant Unipolar Depression
NIERENBERG, A. A., FEIGHNER, J. P., RUDOLPH, R., COLE, J. O., & SULLIVAN, J. (1994) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199412000-00008 · Cited by 198
Restoring invisible and abandoned trials: a call for people to publish the findings
Doshi, P., Dickersin, K., Healy, D., Vedula, S. S., & Jefferson, T. (2013) · BMJ · doi:10.1136/bmj.f2865 · Cited by 190
Does Study Design Influence Outcome?
Rutherford, B. R., Sneed, J. R., & Roose, S. P. (2009) · Psychotherapy and Psychosomatics · doi:10.1159/000209348 · Cited by 158
The mechanisms of tolerance in antidepressant action
Fava, G. A., & Offidani, E. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.026 · Cited by 158
Strengthening clinical effectiveness trials: Equipoise-stratified randomization
Lavori, P. W., Rush, A. J., Wisniewski, S. R., Alpert, J. E., D, M. F. M., Kupfer, D. J., Nierenberg, A. A., Quitkin, F. M., Sackeïm, H. A., Thase, M. E., et al. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01223-9 · Cited by 153
The STAR*D Trial: Revealing the Need for Better Treatments
Insel, T. R., & Wang, P. S. (2009) · Psychiatric Services · doi:10.1176/ps.2009.60.11.1466 · Cited by 150
Barbui, C., Furukawa, T. A., & Cipriani, A. (2007) · Canadian Medical Association Journal · doi:10.1503/cmaj.070693 · Cited by 131
Pigott, H. E. (2015) · The Canadian Journal of Psychiatry · doi:10.1177/070674371506000104 · Cited by 93
Self-citationMAOI efficacy and safety in advanced stage treatment-resistant depression—A retrospective study
Amsterdam, J. D., & Justine Shults, A. (2005) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.06.011 · Cited by 82
Self-citationLeykin, Y., Amsterdam, J. D., DeRubeis, R. J., Gallop, R., Shelton, R. C., & Hollon, S. D. (2007) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.75.2.267 · Cited by 82
Self-citationMcGrath, P. J. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.9.1531 · Cited by 77
Nierenberg, A. A. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.9.1519 · Cited by 69
Fluoxetine efficacy in treatment resistant depression
Amsterdam, J. D., Maislin, G., & Potter, L. S. (1994) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/0278-5846(94)90057-4 · Cited by 62
Self-citationAmsterdam, J. D., Williams, D., Michelson, D., Adler, L. A., Dunner, D. L., Nierenberg, A. A., Reimherr, F. W., & Schatzberg, A. F. (2009) · Neuropsychobiology · doi:10.1159/000226611 · Cited by 39
Self-citationThe STAR*D Trial: Revealing the Need for Better Treatments
Insel, T. R., & Wang, P. (2009) · Psychiatric Services · doi:10.1176/appi.ps.60.11.1466 · Cited by 29
Kirsch, I., Huedo-Medina, T. B., Pigott, H. E., & Johnson, B. T. (2018) · Psychology of Consciousness: Theory, Research, and Practice · doi:10.1037/cns0000164 · Cited by 24
Self-citationAmsterdam, J. D., Lorenzo‐Luaces, L., & DeRubeis, R. J. (2016) · Bipolar Disorders · doi:10.1111/bdi.12442 · Cited by 20
Self-citationIndustry-corrupted psychiatric trials
Amsterdam, J. D., McHenry, L. B., & Jureidini, J. N. (2017) · Psychiatria Polska · doi:10.12740/pp/80136 · Cited by 20
Self-citationAmsterdam, J. D., & Kim, T. T. (2019) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001049 · Cited by 17
Self-citationWorkplace Depression: Personalize, Partner, or Pay the Price
Greden, J. F. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2012.13030382 · Cited by 16
Andrews, P. W., & Amsterdam, J. D. (2020) · Psychiatria Polska · doi:10.12740/pp/120084 · Cited by 11
Self-citationAmsterdam, J. D., & Lorenzo‐Luaces, L. (2018) · Psychiatria Polska · doi:10.12740/pp/98961 · Cited by 4
Self-citation
Research works printed but not linked: 2
- 10.1176/appi.ajp.163.7.1161 · doi:10.1176/appi.ajp.163.7.1161 · Paper page
- Pigott HE , Dubin W , Kirsch I , et al . Call to action: RIAT Reanalysis of the sequenced treatment alternatives to relieve depression (STAR*D) study. BMJ March 6, 2019. Available: https://www.bmj.com/content/346/bmj.f2865/rr-10
Cited by
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
“In patients who underwent multiple rounds of therapy, the probability of response or remission decreased with subsequent treatments, with only 21% response (22/106) and 10% remission (11/106) by the fourth therapy option [18].”
BackgroundAdvancing precision psychiatry and targeted treatments: Insights from immunopsychiatry
Miller, A. H., Berk, M., Bloch, G., Briquet-Laugier, V., Brouillon, C., Cuthbert, B. N., Dantzer, R., Davis, M. C., Picker, L. D., Drevets, W. C., et al. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.01.002 · Cited by 60
Pardossi, S., Fagiolini, A., & Cuomo, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313098 · Cited by 51
“However, when adhering strictly to protocol-specified criteria, the remission rate was approximately 35% [11].”
Spaced Transcranial Direct Current Stimulation for Major Depression
Couture, M., Jodoin, V. D., Bousseau, E., Sarshoghi, A., Nitsche, M. A., Blumberger, D. M., Bolduc, C., Weissman, C. R., Appelbaum, L. G., Daskalakis, Z. J., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240083 · Cited by 24
Constantino, J. L., Godschalk, M., van Dalfsen, J. H., Veraart, J. K. E., Spijker, J., van Exel, E. R., Schoevers, R. A., & Kamphuis, J. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116355 · Cited by 23
“Pigott et al. (2023).”
Metadata
- Authors
- Pigott, H. E., Kim, T., Xu, C., Kirsch, I., & Amsterdam, J.
- Affiliations
- None, Wakefield, Rhode Island, USA
- University of Pennsylvania (US)
- Harvard University (US)
- Corresponding author
- Pigott, H Edmund
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2023-07
- Volume
- 13
- Issue
- 7
- Pages
- e063095
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC10373710
- OpenAlex
- W4385257581
- Cited by
- 93
- References
- 35
- Citations by year
- 2026: 35 · 2025: 37 · 2024: 19 · 2023: 2
- FWCI
- 14.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- HighWire Press Open Archive (submittedVersion)
- Funders
- The RIAT Support Center (N/A)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- major depressive disorder, antidepressant treatment, treatment remission, treatment response, Hamilton Depression Rating Scale, protocol fidelity, selective reporting, citalopram, antidepressant trials, real-world clinical practice
- MeSH terms
- Adult, Antidepressive Agents, Major Depressive Disorder, Depressive Disorder, Major, Humans, Psychotherapy, Citalopram, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.